Science Symposium, 26 May 2014, New Delhi, India Dr Gerald Renner Director Technical Regulatory Affairs Cosmetics Europe EU scenario on alternatives in.

Slides:



Advertisements
Similar presentations
WTO, Trade and Environment Division
Advertisements

International dimension of 3Rs acceptance
The conversion of Saul to St Paul (Michelangelo, 1542) Marcel Leist Doerenkamp-Zbinden Chair For Alternative in vitro Methods, University Konstanz, Konstanz.
EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.
EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.
THE ROLE OF ECVAM IN PROMOTING THE REGULATORY ACCEPTANCE OF ALTERNATIVE METHODS Dr Andrew Worth European Centre for the Validation of Alternative Methods.
1 Development, Implementation and Use of Alternative Test Methods in Regulatory Hazard Assessment in OECD Member countries Herman B.W.M.Koëter, Principal.
1. European Commission GHS Implementation Status in the European Community ICCM Dubai UNITAR Side event 4-6 February 2006 Eva Sandberg European Commission.
Regulatory Framework Leigh Shaw, Director.
1. European Commission Status GHS Implementation in the European Community Global Thematic Workshop on Strengthening Capacities to Implement the GHS Johannesburg.
1. European Commission GHS Implementation Status in the European Community FORUM V Budapest UNITAR Side event 27 September 2006 Wolfgang Hehn European.
Roundup and birth defects: How the public is being kept in the dark Claire Robinson Earth Open Source December.
Options for a Voluntary Peer Review on Fossil-Fuel Subsidies.
EDSP Validation Gary E.Timm Senior Technical Advisor Office of Science Coordination and Policy U.S. Environmental Protection Agency.
Disability Rights Expanding Accessible Markets Kick-off Meeting 23 rd -25 th November, 2011 Brussels, Belgium.
ECVAM Key Area Sensitisation: Overview on Activities Silvia Casati, Chantra Eskes.
Value of in vitro assays in your REACH dossier Frédérique van Acker 18 November 2014.
Evolution of ICCVAM ◊National Toxicology Program Develop and validate improved test methods ◊NIH Revitalization Act: P.L Develop and.
Introduction to REACH Awareness and Compliance Assistance Workshop for the Exporters of Apparel Date: 3rd August 2011 Venue: India Habitat Centre, New.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
REACH in the eyes of a downstream user The changing market of cosmetic ingredients Aleksandra Sołyga-Żurek Warsaw, 23.XI.2011.
Preclinical Safety Assessment of Cosmetics & Toiletries Raman Govindarajan, MD, PhD. Regional Director Medical and Scientific Affairs Johnson and Johnson.
Adopting the Globally Harmonized System (GHS) - A Practical Guide September 8, 2010.
CONTRIBUTION OF THE SCCNFP TO
SSSG 2007 Global Harmonization System. What is GHS ? GHS is an international system designed to standardize the communication of hazardous substances.
June 2008 Proposal for a Regulation to replace Directive 91/414/EEC July 2008 T Lyall.
Development and application of guidance documents – industry view Dr Martin Schaefer ECCA-ECPA Conference March 2014.
International Initiatives and the U.S. HPV Challenge Program Ken Geiser, PhD Lowell Center for Sustainable Production University of Massachusetts Lowell.
Preparing for REACH implementation: The RIP process Dimosthenis A. Sarigiannis, PhD Institute for Health and Consumer Protection DG Joint Research Centre.
EDSP’s Approach to Test Protocol Validation Office of Science Coordination and Policy U.S. Environmental Protection Agency.
© OECD A joint initiative of the OECD and the European Union, principally financed by the EU. Quality Assurance José Viegas Ribeiro IGF, Portugal SIGMA.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Support for the Modernisation of the Mongolian Standardisation system – EuropeAid/134305/C/SER/MN Training on standardisation Support to the Modernisation.
Mike Comber Consulting TIMES-SS Assessment of skin sensitisation hazard Presented on behalf of the TIMES-SS consortia.
EU Legislation in the field of environment – key developments in 2007 and rd ECENA Plenary Meeting 18 September 2008.
CLASSIFICATION AND LABELLING OF DANGEROUS SUBSTANCES FROM CURRENT EU LEGISLATION TO THE GLOBALLY HARMONISED SYSTEM Zagreb, 12 December 2006 Dr. Elisabet.
Nanomaterials classification and labelling – status of work undertaken in GHS (Globally Harmonized System of Classification and Labelling of Chemicals)
1 DG Enterprise & Industry European Commission Conference on Better Regulation: Practical Steps Forward Reykjavík 6 June 2006 OVERVIEW OF THE BETTER REGULATION.
1 EUROPEAN COMMISSION CLIMATE CHANGE UNIT European Climate Change Programme: legislative action fluorinated gases Phil Callaghan European Commission DG.
The road to EU/EMU Membership 1/3 According to Article 49 (Treaty on EU) any European state can apply for the full membership to the EU. In order to join.
ECVET som teknisk rammeverk Oppstartsseminar Oslo
The Commission's Impact Assessment system 18 September 2014 María Dolores Montesinos Impact Assessment unit Secretariat General 1.
The information contained in this presentation is proprietary to Colorcon and may not be used or disseminated inappropriately. Global Harmonization of.
1 PROPOSAL TO MERGE TACHOGRAPH CARD AND DRIVING LICENCE Alison Davies, DVLA, United Kingdom.
Specific Safety Requirements on Safety Assessment and Safety Cases for Predisposal Management of Radioactive Waste – GSR Part 5.
OF COSMETIC PRODUCTS IN THE EU
Health & Consumers Directorate General
OECD’s work on Adverse outcome pathways
Phase One – Project Initiation and Set Up Project Name Your Area Health Service.
Florence Forum, November 2008 Regulation (EC) 1228/ ERGEG Compliance Monitoring.
CONFERENCE IMPLEMENTATION OF MARKETS IN FINANCIAL INSTRUMENTS DIRECTIVE -MiFID- Split, June 2007 OPENING SPEECH Ante Samodol President of the Board.
Better regulation in the Commission Jonathon Stoodley Head of Unit C.1 Evaluation, Regulatory Fitness and Performance Secretariat General of the European.
June 2009 Regulation on pesticide statistics Pierre NADIN ESTAT E1- Farms, agro-environment and rural development
Purpose, Scope and Application of the GHS 1. The Globally Harmonized System of Classification and Labeling of Chemicals (GHS) is a rational and comprehensive.
The new chemicals risk matrices. Workshop focus use of new online categorisation tools criteria used to categorise new chemicals under the proposed framework.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
NICNAS Reforms Community Stakeholder Workshop. Input from non-industry stakeholders on NICNAS Reforms Working within parameters of Government decision.
We personally care 31 May 2016 – Working Group on Cosmetic Products EU Cosmetics Regulation – Article 15.2 Criteria for exempting CMR1A and 1B from being.
The EU Cosmetics Regulation Matthew A. Kopetski Commercial Specialist U.S. Mission to the European Union February 21 st, 2013.
Update on recent developments in the ed regulatory landscape in Europe
OECD Principles of GLP and Test Guidelines
EU Reference Centres for Animal Welfare
The 3Rs principles for safety testing of human and veterinary medicines A view on the EU regulatory developments in 3Rs (replacement, reduction, refinement)
Safety Tests in Cosmetics
Safety Tests in Cosmetics
ECVAM as EU-RL according to 2010/63
CONCLUSIONS OF DEBATES
Health & Consumers Directorate General
Raising the Standards in European Homeopathy
International Initiatives and the U.S. HPV Challenge Program
Presentation transcript:

Science Symposium, 26 May 2014, New Delhi, India Dr Gerald Renner Director Technical Regulatory Affairs Cosmetics Europe EU scenario on alternatives in cosmetic safety evaluation State-of-play, impact & recommendations 1

Science Symposium, 26 May 2014, New Delhi, India I.EU measures affecting animal testing II.State-of-the-art of science III.Impact of EU regulatory measures IV.Recommendations 2Overview

Science Symposium, 26 May 2014, New Delhi, India I.EU measures affecting animal testing 3

Science Symposium, 26 May 2014, New Delhi, India EU measures affecting animal testing Testing and marketing bans “for the purpose of the Cosmetics Regulation” successively entering into force between 2004 and

Science Symposium, 26 May 2014, New Delhi, India Ban on animal testing All human health “endpoints” irrespective of availability of ATTs Ingredients where AATs are a) ECVAM validated and b) adopted in EU legislation Marketing ban Cosmetic products and their ingredients Derogation until-13 ■ repeated dose tox. ■ reproductive tox. ■ carcinogenicity ■ toxicokinetics most tox. endpoints Complete testing ban EU measures affecting animal testing 2004 Cosmetic products 5

Science Symposium, 26 May 2014, New Delhi, India European Commission Interpretation In 2013, the European Commission clarified its own interpretation of the scope of the ban explaining that it is not a blanket ban: «The Commission considers that animal testing that has clearly been motivated by compliance with non-cosmetics related legislative frameworks should not be considered to have been carried out ‘in order to meet the requirements of this Directive/Regulation’ » «The Commission considers that the marketing ban is triggered by the reliance on the animal data for the safety assessment under the Cosmetics Directive/Regulation, not by the testing as such. In case animal testing was carried out for compliance with cosmetics requirements in third countries, this data cannot be relied on in the Union for the safety assessment of cosmetics. » 6

Science Symposium, 26 May 2014, New Delhi, India European Commission Interpretation – Products are banned only if ingredients or products tested for cosmetics purposes (in or outside of the EU) – Possibility to market products if ingredients tested for multiple purposes (in and outside of the EU) – The marketing ban is only triggered by the use of data – In exceptional circumstances: derogation for existing, non- replacable ingredient of which the use raises a specific human health problem (substantiation required) 7

Science Symposium, 26 May 2014, New Delhi, India II.State-of-the-art of science 8

Science Symposium, 26 May 2014, New Delhi, India Timetables for phasing out Animal tests A first technical report on timetables for the phasing out of animal testing was prepared by nominated independent experts in 2003 and published in 2005 Covered all toxicological endpoints relevant for cosmetics (ingredients) testing 9

Science Symposium, 26 May 2014, New Delhi, India Current status and Outlook beyond the ban Alternative (non-animal) methods for cosmetics testing: current status and future prospects 2010 Adler, S. et al. (2011) Arch. Toxicol., 85: Review considered the toxicological endpoints important for the 2013 marketing ban deadline Revealed that the scientific basis to fully replace animal testing for the five toxicological key areas is still not established (additional time beyond 2013 needed) Confirmed that it could take at least another 7 – 9 years for the replacement of some of the current in vivo animal tests necessary for the safety assessment 10

Science Symposium, 26 May 2014, New Delhi, India OECD Guidelines for Toxicology studies  OECD Guidelines: Collection of internationally agreed test methods used by government, industry and independent laboratories.  Mutual Acceptance of Data (MAD): test data generated in any member country in accordance with OECD Test Guidelines and Principles of Good Laboratory Practice (GLP) shall be accepted in other member countries  Ability for non-OECD countries to take part as full members in this system. 11

Science Symposium, 26 May 2014, New Delhi, India OECD Guidelines for Toxicology studies  OECD Guidelines: Collection of internationally agreed test methods used by government, industry and independent laboratories.  Mutual Acceptance of Data (MAD): test data generated in any member country in accordance with OECD Test Guidelines and Principles of Good Laboratory Practice (GLP) shall be accepted in other member countries  Ability for non-OECD countries to take part as full members in this system. The OECD tool box still mainly contains in vivo studies. These concern studies on rodents. 12

Science Symposium, 26 May 2014, New Delhi, India R&D Test Submission & Review Optimisation GLP Prevalidation Full Validation Project proposal Regulatory acceptance ECVAM Review/Validation Minimum 4-5 years OECD TG Acceptance Minimum 2-3 years Peer review Traditional Regulatory Acceptance Process at ECVAM and OECD R&D > 5 years 13

Science Symposium, 26 May 2014, New Delhi, India Status of Science GENOTOXICITY EYE IRRITATION ACUTE TOXICITY GENOTOXICITY EYE IRRITATION ACUTE TOXICITY SKIN IRRITATION PHOTOTOXICITY PERCUTANEOUS ABSORPTION SKIN CORROSION SUBACUTE SUBCHRONIC TOXICITY CARCINO- GENICITY SKIN SENSITISATION + PHOTO- SENSITISATION SKIN SENSITISATION + PHOTO- SENSITISATION TOXICOKINETICS REPRO- TOXICITY (including TERATO- GENICITY) Fine tuning 2016 ADVANCED Regulatory Acceptance COMPLETED Test Strategy > 2020 Research Test Strategy > 2020 Research Tests > 2020 Qualification Test Strategy < 2020 Test Strategy < 2020 Qualification Test Strategy > 2020 Research 14

Science Symposium, 26 May 2014, New Delhi, India Available validated Alternative Methods for Human Health Safety Assessments in the SCCS Notes of Guidance Endpoints Acute toxicity Skin corrosivity Skin irritation Eye irritation Skin sensitisation Phototoxicity Toxicokinetics Repeated dose toxicity Reproduction toxicity Mutagenicity/Genotoxicity Carcinogenicity 3Rs Reduction/refinement (oral/inhalation) Full replacement (TG 430, 431) Full replacement (TG 439) Partial replacement 1 (TG 437, 438, 460) No replacement Full replacement (TG 432) No replacement Partial replacement 2 No replacement 1 Only for compounds causing "serious eye damage" (category 1 of the GHS), or not requiring classification for eye irritation or serious eye damage according to the GHS. 2 Only for negative results, not possible to follow-up positive/false positive results since animal data would be required. 15

Science Symposium, 26 May 2014, New Delhi, India -Only for a limited number of toxicological endpoints, replacement methods are available and validated (Report by the European Commission Joint Research Centre (JRC) 1 ) -Replacement methods for skin allergy testing potentially available within 2-4 years but for the more complex endpoints a timeline is difficult to anticipate -State-of-the-art of regulatory accepted test methods (OECD Test Guidelines 2 ) 1 progress-report-development-validation-regulatory-acceptance-alternative- methods progress-report-development-validation-regulatory-acceptance-alternative- methods 2 chemicals-section-4-health-effects_ chemicals-section-4-health-effects_ Science - Concluding remarks 16

Science Symposium, 26 May 2014, New Delhi, India More time and efforts are needed to develop the complete set of alternative methods: -New internationally agreed tools and testing approaches required for successful development of replacements -New streamlined validation criteria required for mechanistic tests; not realistic that a single screening test should take 6-8 years to reach regulatory acceptance Science - Concluding remarks 17